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Beta-phenylethylamine (PEA), the parent compound of
both methamphetamine and (-)-deprenyl, has two effects:
it is a releaser of catecholamines and a natural enhancer
substance. Methamphetamine, the closest mother com-
pound of (-)-deprenyl, acts like PEA. (-)-Deprenyl was the
first PEA derivative which lost the releasing property but
preserved the enhancer effect. We elaborated a method on
isolated rat brain stem, which allowed to measure the
enhancer effect of (-)-deprenyl and to detect how the
releasing effect of methamphetamine hinders the recogni-
tion of its enhancer effect. We fill up the intraneuronal
transmitter stores of the noradrenergic neurons in an iso-
lated rat brain stem with [3H]noradrenaline and thereafter
continuously measure the amount of the labeled trans-
mitter released from the organ. Electrical stimulation
increases the amount of [3H]noradrenaline released into
the bathing fluid. Due to its enhancer effect, 2 μg/ml (-)-
deprenyl significantly increases the amount of labeled
transmitter to the same stimulation. The addition of 2 μg/
ml amphetamine or methamphetamine to the bathing
fluid in the resting state rapidly leads to the continuous
release of a high amount of [3H]noradrenaline into the
organ bath and electrical stimulation is unable to further
increase the amount of the labeled transmitter, thus hin-
dering the detectability of the enhancer effect.
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